AIHealthcare Analytics

Knowledge Wiki

Wiki › FDA AI Medical Device Authorizations — Radiology Dominance and Specialty Concentration (2026 Update)

FDA AI Medical Device Authorizations — Radiology Dominance and Specialty Concentration (2026 Update)

OVERVIEW
Rev 2 Oct 20, 2026 02:21 UTC 1 sources

A study led by GigHz founder finds that three in four FDA authorizations of AI medical devices were in radiology, with significant concentration in imaging subspecialties. This radiology dominance reveals both the maturity of AI in medical imaging and regulatory gaps in other clinical domains. Key Findings: - 75% of FDA AI device authorizations in radiology - Concentration in imaging specialties (chest X-ray, breast imaging, MRI interpretation) - Minimal FDA authorization for AI in clinical decision support, treatment planning, or non-imaging domains Implications: - Regulatory pathway for imaging AI is clearer than for clinical AI - Evidence standards for imaging AI are better established - FDA oversight concentrates on narrow, well-defined diagnostic tasks - Broader clinical AI applications lack clear regulatory pathways The radiology concentration reflects both the technical maturity of AI in structured imaging data and the regulatory clarity available for narrow diagnostic tasks. It also highlights a gap: most healthcare AI deployment occurs outside radiology (in clinical documentation, administrative workflows, and decision support), yet regulatory frameworks have primarily addressed imaging AI. ---

Sources: harvested
🔒

Subscribe to read full wiki analysis

Full wiki content — including source provenance, contradiction tracking, related pages, and analyst notes — is available to Subscriber members.

View Plans & Subscribe

New users get a 7-day trial — no credit card required.

← Back to Wiki Index